Covidien touts 510(k) clearance for its LigaSure Maryland jaw open/laparoscopic sealer/divider.
Covidien (NYSE:COV) won 510(k) clearance from the FDA for its LigaSure Maryland jaw open/laparoscopic sealer/divider, the company announced this week.
Covidien said it's pulling the plug on its OneShot renal denervation device, citing the slow development of the hypertension market.
Covidien (NYSE:COV) said it plans to wind down its OneShot renal denervation program, largely due to "slower than expected development of the renal denervation market," meaning the end for a U.S. clinical trial of the high blood pressure device.
In case you couldn't make it to sunny San Francisco, here are some of the best medical device stories that came out of the J.P. Morgan Healthcare conference this week.
Covidien hands its Confluent Surgical product line over to Integra LifeSciences in a deal worth up to $260 million.
New York's AngioDynamics closes the books on an employee discrimination lawsuit with neither party admitting wrongdoing.
Medtech maker AngioDynamics (NSDQ:ANGO) finally put to bed a former employee's discrimination lawsuit, ending the quarrel with neither party admitting to any wrongdoing.
Covidien CEO José Almeida says the medical device company is willing to pull resources from its businesses in the U.S. and Europe to bolster its footprint in emerging markets.
Covidien (NYSE:COV) helped finance the buyout of a pair of small medical device companies in Brazil and China by pulling resources from is operations in the U.S. and Europe, CEO José Almeida told investors this morning at the J.P. Morgan Healthcare conference.
The FDA issues a Class I recall for Covidien’s Puritan Bennett 840 ventilator due to a software problem.
The FDA issued a Class I recall for Covidien's (NYSE:COV) Puritan Bennett 840 Series Ventilator, because of a software issue that could cause the device to shut down.